Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
— Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven’s proprietary MoDE(TM) and next-generation, highly selective TRAP(TM) degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: — IgA […]